Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
A case of leukocytoclastic vasculitis after use of sorafenib (Nexavar®)A Case of Leukocytoclastic Vasculitis after Use of Sorafenib (NexavarⓇ)
- Authors
- Kim, H.-J.; Kim, J.-H.; Kim, J.-B.; Kim, H.-K.; Ko, Y.-S.; Joh, O.-J.; Lee, J.-S.; Kye, Y.S.
- Issue Date
- May-2008
- Publisher
- 대한피부과학회
- Keywords
- Leukocytoclastic vasculitis; Nexavar®; Sorafenib
- Citation
- Korean Journal of Dermatology, v.46, no.5, pp 648 - 651
- Pages
- 4
- Journal Title
- Korean Journal of Dermatology
- Volume
- 46
- Number
- 5
- Start Page
- 648
- End Page
- 651
- ISSN
- 0494-4739
- Abstract
- Sorafenib (Nexava®) is an oral multikinase inhibitor that was recently approved for use in metastatic renal cancer. It is currently undergoing investigation for the treatment of locally advanced renal cancer and in other tumor types. It has a broad spectrum of activity in treating multiple tyrosine kinases, including angiogenic factors VEGFR and PDGFR. Common cutaneous toxicities experienced with sorafenib include facial and scalp erythema, hand-foot syndrome, splinter hemorrhages, and alopecia. We report a case of a 57 year-old man diagnosed as renal cell carcinoma with distant metastaisis, who developed a leukocytoclastic vasculitis on the extremities after use of sorafenib.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.